---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338097"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2026-08-06T20:19:39+00:00"
generated_at: "2026-08-06T20:22:28.157400+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q2 2026 net loss $3.3M; cash $11.5M, runway into Q1 2027

## Summary
- Net loss of $3.3M ($0.87 per share) for Q2 2026 vs. $2.4M ($28.04) in Q2 2025.
- Cash and cash equivalents $11.5M as of June 30, 2026, up from $10.7M at Dec 31, 2025.
- Operating cash burn $2.6M in Q2 2026 vs. $1.9M in Q2 2025.
- Phase 2/3 AKI trial startup progressing; independent market assessment shows $94B TAM for Gemini.
- Management expects current cash to fund operations through Q1 2027.

## SEC filing metadata
- accession: 0001193125-26-338097
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2026-08-06T20:19:39+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/0001193125-26-338097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/revb-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338097
- JSON: https://secwatch.observer/filing/0001193125-26-338097.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.